Protagonist Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTGX research report →
Range $110 – $165
Price Chart
About the company
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders.
- CEO
- Dinesh V. Patel
- IPO
- 2016
- Employees
- 132
- HQ
- Newark, CA, US
Get TickerSpark's AI analysis on PTGX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.77B
- P/E
- -75.65
- Fwd P/E
- 32.07
- PEG
- 0.21
- P/S
- 118.37
- P/B
- 13.54
- EV/EBITDA
- -75.34
- Div Yield
- 0.00%
- Gross Margin
- 99.45%
- Op Margin
- -192.36%
- Net Margin
- -154.88%
- ROE
- -17.76%
- ROIC
- -21.29%
Latest fiscal year · YoY change
- Revenue
- $46.02M-89.4%
- Gross Profit
- $44.79M-89.7%
- Op Income
- $-158,127,000
- Net Income
- $-130,149,000-147.3%
- EPS
- $-2.05-145.9%
- OCF Growth
- -68.7%
- FCF Growth
- -69.3%
- 52W High
- $143.29
- 52W Low
- $50.48
- 50D MA
- $114.07
- 200D MA
- $94.66
- Beta
- 1.79
- RSI (14)
- 60
- Avg Volume
- 722.35K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the PTGX Q4 '20 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 81.6%
- Shares Outstanding
- 64.31M
- Float Shares
- 52.49M
of shares held by institutions
331 13F filers
Buy/sell ratio 0.41. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 9.78M | ▲ 63.37K |
| Farallon Capital Management LLC | 6.35M | ▲ 204.90K |
| Vanguard Group Inc | 5.41M | ▲ 1.16M |
| Ubs Group AG | 5.18M | ▲ 2.41M |
| Rtw Investments, LP | 5.06M | 0 |
| Wellington Management Group Llp | 3.60M | ▲ 428.22K |
| State Street Corp | 3.12M | ▼ 82.98K |
| Janus Henderson Group PLC | 2.89M | ▲ 241.55K |
| Johnson & Johnson | 2.45M | 0 |
| Invesco Ltd. | 2.16M | ▲ 596.83K |
| Geode Capital Management, LLC | 1.67M | ▲ 216.44K |
| Price T Rowe Associates Inc | 1.67M | ▲ 264.76K |
Held by 354 ETFs
Biggest fund positions in PTGX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 23, 26 | Waddill William D. | other | 9,000 |
| Jun 23, 26 | Waddill William D. | sell | 9,000 |
| Jun 23, 26 | Waddill William D. | other | 9,000 |
| Jun 10, 26 | Waddill William D. | other | 6,000 |
| Jun 10, 26 | Waddill William D. | other | 3,000 |
| Jun 10, 26 | Waddill William D. | other | 6,000 |
| Jun 10, 26 | Waddill William D. | sell | 9,000 |
| Jun 10, 26 | Waddill William D. | other | 3,000 |
| May 29, 26 | Waddill William D. | other | 9,000 |
| May 29, 26 | Waddill William D. | sell | 9,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PTGX coverage
Recent articles, reports, and earnings notes.
Want a deeper read on PTGX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Protagonist Therapeutics Reports Granting of Inducement Awards
accessnewswire.com · Jul 16
Best Momentum Stocks to Buy for July 13th
zacks.com · Jul 13
New Strong Buy Stocks for July 13th
zacks.com · Jul 13
New Strong Buy Stocks for July 9th
zacks.com · Jul 9
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?
zacks.com · Jul 8
PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?
zacks.com · Jul 7
Protagonist Therapeutics Reports Granting of Inducement Awards
accessnewswire.com · Jul 1
Protagonist Therapeutics Reports Granting of Inducement Awards
accessnewswire.com · Jun 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Bullish or bearish?
Where do you stand on PTGX?